임상 한눈에 보기

• 2건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 2건 · 완료/종료 0건
• Phase: Phase 1, Phase 2
• Status: Active, not recruiting
• 주요 endpoint: Number and type of Adverse Events (AE) · Duration of persistence of AMT-130 in the brain · Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Adverse Events · Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Blood Pressure · Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Respiratory Rate
• 등록 대상자(표본 합산): 약 57명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.